ARTICLES BY LOUIS GARGUILO
-
![decisions ahead-choose your path-GettyImages-1271417161]( "When Should You Select Your Supply Partner?")
When Should You Select Your Supply Partner?9/19/2024In this part two, James Doherty, President and Chief Development Officer, provides readers with a window into the contracting strategy of Acumen Pharmaceuticals, a biotech developing a novel therapeutic for the treatment of Alzheimer’s disease (AD). Acumen has announced it entered a CDMO contract for both clinical and any future commercial supply.
-
![Fitness working out-GettyImages-1367403507]( "If The CDMO Shoe Fits, Wear It Now")
If The CDMO Shoe Fits, Wear It Now9/16/2024Acumen Pharmaceuticals, a clinical-stage biopharmaceutical developing a novel therapeutic for the treatment of Alzheimer’s, selected its manufacturing partner early on, and told the world about it. Chief Editor Louis Garguilo asked the chief development officer about that strategy.
-
![Bored worker throwing paper airplane-GettyImages-512753786]( "Warning To U.S.-Based CDMOs: Don't Get Complacent")
Warning To U.S.-Based CDMOs: Don't Get Complacent9/9/2024How could I not ask him for an opinion regarding our vigorously pursued editorials on the WuXi Apptec–BIOSECURE Act. After all, Reza Oliyai has outsourced a myriad of development and manufacturing services to hundreds of CDMOs around the world. He did so at Gilead for decades, and since as the CEO of his eponymous consulting company. His response did not disappoint.
-
![bottle filling machine-GettyImages-1268181219]( "The Most Difficult Outsourcing Tasks")
The Most Difficult Outsourcing Tasks9/6/2023Hint: According to long-termed Pfizer supply-chain professional Francis Dumont, it is sterile-fill. Learn about that and much more on working effectively with CDMOs to optimize production.
-
![GettyImages-847192432]( "Multiplying Forces Of Clinical Supply Outsourcing")
Multiplying Forces Of Clinical Supply Outsourcing1/30/2023There are a number of varying and converging forces baring down on sponsors looking for CROs/CDMOs who can provide a full slate of services around their clinical-trial material. Both CDMOs and sponsors need to add or subtract from their strategies to adjust.
-
![GettyImages-1336200081]( "Beware The Manufacturing Bottleneck: Lessons From Inside")
Beware The Manufacturing Bottleneck: Lessons From Inside6/6/2022Steven Kelly, President & CEO, Carisma, a biotech with a CAR M therapy in phase one, is a repeat-CEO. “I’ve had a varied experience, and different functional responsibilities,” he says, "but when I think about manufacturing, two experiences stand out for me.”
Louis Garguilo
Click here to e-mail Louis
Louis Garguilo is chief editor of Outsourced Pharma, and is considered a leading authority on the art and science of drug development and manufacturing outsourcing. He studied public relations and journalism at Syracuse University (and holds a Master’s in English). His widely read editorials are based on in-depth analysis and interviews with industry executives and professionals. Editorials are written in an engaging and unique style that guide readers through the macro aspects and subtle nuances of outsourcing, and working with contract development and manufacturing organizations (CDMOs). Garguilo also serves as moderator for the various Outsourced Pharma Live webinars held throughout the year.
Prior to joining Outsourced Pharma in 2014, Garguilo spent a decade at a global pharmaceutical contract research, development and manufacturing organization, leaving the industry after attaining the role of vice president, business development and marketing. Additionally, he has served under the governor of New York in the state’s economic development agency, as liaison to the pharmaceutical/biotechnology industry; as chief strategic officer for an e-learning software company; and spent most of the ‘80s and ‘90s in Japan as an educator, author, and communications consultant.